期刊文献+

过氧化物酶体增殖物激活受体γ与糖尿病肾病 被引量:1

Peroxisome proliferator-activated receptor-alpha and diabetic nephropathy
暂未订购
导出
摘要 过氧化物酶体增殖物激活受体(peroxisomeproliferator-activatedreceptor,PPAR)属于核受体超家族成员,可分为三种亚型(PPARα、PPARβ/δ、PPARγ),PPARγ在脂肪形成、脂质代谢、胰岛素敏感性、炎症反应、动脉粥样硬化、血压调节等方面发挥重要作用,本文将就其与糖尿病肾病的关系作一综述。 Peroxisome proliferator-activated receptor (PPAR), a member of nuclear hormone receptor superfamily, has 3 subtypes, namely, PPARα, PPARβ/δ, and PPARγ; among them PPARγ plays an important role in adipogenesis, lipid metabolism, insulin sensitivity, inflammation, atherosclerosis, and blood pressure controlling. This article reviews the relationship between PPARγ and diabetic nephropathy.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2006年第12期1372-1374,共3页 Academic Journal of Second Military Medical University
关键词 糖尿病肾病 PPARΓ 噻唑烷二酮类 diabetic nephropathies PPAR gamma thiazolidinediones
  • 相关文献

参考文献6

二级参考文献58

  • 1[2]Spiegelman BM.PPAR-γ:adipogenic regulator and thiazolidinedione receptor[J].Diabetes,1998,47:507-514.
  • 2[3]Law RE,Goetz S,Xi XP,et al.Expression and function of PPAR-γ in rat and human vascular smooth cells[J].Circulation,2000,101:1311-1318.
  • 3[4]Ricote M,Huang J,Fajas L,et al.Expression of the peroxisome proliferator-activated receptor gamma (PPAR-γ) in human athrosclerosis and regulation in macrophages by colony stimulating factors and oxidized low-density lipoprotein[J].Proc Natl Acad Sci USA,1998,23:7614-7619.
  • 4[5]Jiang C,Ting AT,Seed B.PPAR-γ agonists inhibit production of monocyte inflammatory cytokines[J].Nature,1998,391:82-86.
  • 5[6]Jackson SM,Parhami F,Xi XP,et al.Peroxisome proliferator-activated receptor activators target human endothelial cell to inhibit leukocyte-endothelial cell interaction[J].Arterioscler Thromb Vasc Biol,1999,2094-2104.
  • 6[7]Pasceri V,Wu HD,Willerson JT,et al.Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators[J].Circulation,2000,101:235-238.
  • 7[8]Tontonoz P,Nagy L,Alverez JG,et al.PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL[J].Cell,1998,93:241-252.
  • 8[1]Bishop-Bailey D.Peroxisome proliferator-activated receptors in the cardiovascular system[J].Br J Pharmacol,2000,129:823-834.
  • 9Mitsuhiro F, Reiji T, Makiko Y, et al. Troglitazone(CS-045)ameliorates albuminuria in streptozotocin-indueed diabetic rats. Metabolism, 1997,46(9) :98
  • 10American Diabetes Association. Position statement:Disbeticnephropathy.DiabetesCare, 1998, 21 (3): S50

共引文献23

同被引文献27

  • 1张晓燕,陈丽红,管又飞.PPAR家族及其与代谢综合征的关系[J].生理科学进展,2005,36(1):6-12. 被引量:39
  • 2郭延军,石益海,李云,刘翠英,高秀丽,边晓霞.糖尿病肾病中过氧化物酶体增殖物激活受体作用的研究进展[J].中国实验诊断学,2005,9(3):480-480. 被引量:1
  • 3张超,管金发.过氧化物酶体增殖物激活受体γ与糖尿病肾病研究进展[J].内科理论与实践,2006,1(2):141-143. 被引量:2
  • 4Young BA,Johnson RJ,Alpers CE,et al.Cellular events in the evolution of experimental diabetic nephropathy.Kidney Int,1995,47:935.
  • 5Megyesi J,Price PM,Tarnayo E,et al.The lack of a functional P21WAF1/CIP1 gene ameliorates progression to chronic renal failure.Proc Natl Acad SCI USA,1999,96:108 -130.
  • 6Lars Tatenhorst,EricHahnen,andMichaelT.HenekaPeroxisome Proliferator-Activated Receptors(PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors Hindawi Publishing Corporation PPAR Research,2008:9.
  • 7Jones JR,Barrick C,Kim KA,et al.Deletion of PPARγ in adipose tissue of mice protects against high fat diet induced obesity and insulin resistance,Proceedings of the National Academy of Sciences of the United States of America,2005,102 (17):6207-6212.
  • 8Weimin He PPARγ2Pro12Ala Polymorphism and Human Health.Hindawi Publishing Corporation PPAR Research,2009:15.
  • 9解汝娟,陈香美.PPARγ2基因多态性与疾病的关系.军医进修学院博士学位论文,2009:81-85.
  • 10Yen CJ,BeamerB A,NegriC,et al.Moleeular seanning of the human peroxisome proliferator 2 aetivated receptorγ(PPARγ) genein diabetie Caueasians:identifieation of a Prol2Ala PPARγ2 mutation.Bioehem BioPhys Res Comfnun,1997,241:270-274.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部